首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2367篇
  免费   108篇
  国内免费   30篇
耳鼻咽喉   4篇
儿科学   95篇
妇产科学   27篇
基础医学   452篇
口腔科学   77篇
临床医学   280篇
内科学   527篇
皮肤病学   112篇
神经病学   47篇
特种医学   269篇
外科学   214篇
综合类   57篇
预防医学   86篇
眼科学   25篇
药学   168篇
中国医学   1篇
肿瘤学   64篇
  2016年   21篇
  2015年   26篇
  2014年   23篇
  2013年   78篇
  2012年   24篇
  2010年   50篇
  2009年   33篇
  2008年   24篇
  2007年   48篇
  2006年   49篇
  2005年   28篇
  2004年   24篇
  2003年   29篇
  2002年   23篇
  2001年   38篇
  2000年   27篇
  1999年   40篇
  1998年   86篇
  1997年   96篇
  1996年   105篇
  1995年   73篇
  1994年   78篇
  1993年   77篇
  1992年   51篇
  1991年   39篇
  1990年   51篇
  1989年   80篇
  1988年   72篇
  1987年   59篇
  1986年   60篇
  1985年   44篇
  1984年   60篇
  1983年   31篇
  1982年   34篇
  1981年   37篇
  1980年   50篇
  1979年   24篇
  1978年   30篇
  1977年   40篇
  1976年   43篇
  1975年   38篇
  1972年   26篇
  1971年   21篇
  1970年   23篇
  1965年   51篇
  1964年   50篇
  1963年   47篇
  1962年   41篇
  1961年   40篇
  1960年   65篇
排序方式: 共有2505条查询结果,搜索用时 343 毫秒
991.
祁州漏芦蜕皮甾酮类化学成分的研究   总被引:14,自引:0,他引:14  
从祁州漏芦[Rhaponticum uniflorum(L.)DC.]的根中,分离出三个蜕皮甾酮类化合物Ⅰ,Ⅱ,Ⅲ,其中Ⅱ根据UV,IR,MS,13CNMR,1HNMR,1H-1HCOSY,1H-1HNOESY,1H-13C COSY,及CD谱确定其结构为(20R,22R,24S)-2β,3β,11α,14α,20,22,24-heptahydroxy-5β-cholest-7-en-6-one,为一新化合物,命名为漏芦甾酮(rhaponfisterone)。化合物Ⅰ和Ⅲ分别鉴定为蜕皮甾酮(ecdysterone)和土克甾酮(turkesterone)。  相似文献   
992.
993.
994.
Thirty eight children aged between 2 and 4 years with three or more episodes of wheezing were studied to evaluate the role of eosinophil inflammation and its relation to persistence of wheezing two years later. Serum eosinophilic cationic protein, total eosinophil count, total IgE, skin prick test, and clinical features were evaluated at visit 1. Two years later at a second clinical evaluation the children were separated into two groups: group 1, those with persistent wheezing (n = 20); group 2, those who had been asymptomatic over the past six months (transient wheezing) (n = 18). Mean (SEM) eosinophilic cationic protein at visit 1 was higher in group 1 than in group 2 (29.63 (5.16) v 14.42 (2.77) micrograms/l), and the probability of continuing wheezing at age 5 years was greater in children with values > or = 20 micrograms/l at visit 1 than in those with lower values (relative risk = 2.88, 95% confidence interval 1.42 to 5.87, p < 0.001). Eosinophil inflammation is present from the beginning of the disease in the children who are going to continue with wheezing at age 5 years. The measurement of serum eosinophilic cationic protein may help in evaluating which wheezing infants are going to continue with asthma in the future.  相似文献   
995.
The effect of HLA-B27 polymorphism on antigen presentation was analysed by comparing the binding of three Epstein-Barr virus-derived peptide epitopes to HLA-B27 subtypes with their immunogenicity and antigenicity in the context of these subtypes. The effect of altering the major anchor residue Arg2 on binding or on recognition by peptide-specific cytotoxic T lymphocytes (CTL) was also examined. The three peptides bound significantly to all the B*2701-B*2706 subtypes. This did not correlate with the peptides being immunogenic or recognized by specific CTL in the context of only particular subtypes. In addition, of the three viral epitopes tested, those that were immunogenic in B*2702- or B*2705-restricted responses bound to these subtypes less efficiently than one peptide that was immunogenic only in the B*2704 context. Thus, among several potentially immunogenic peptides from the same virus, the antiviral response is not necessarily directed against the one that binds best to the restricting subtype. These results indicate that HLA- B27 polymorphism influences antigen presentation in ways other than simply peptide affinity. Synthetic analogues lacking the canonical Arg2 motif of HLA-B27-bound peptides, even when binding much worse to the restricting subtype, were recognized equally by CTL specific for the parental peptide. This indicates that Arg2 is not required to maintain the structure of the epitope. The implications of these results for pathogenetic models of HLA-B27-associated disease are discussed.   相似文献   
996.
Dynamic regulation of gastric autoimmunity by thyroid hormone   总被引:1,自引:0,他引:1  
  相似文献   
997.
Gastroesophageal reflux disease(GERD) usually requires long-term therapy. Treatment strategies include proton pump inhibitor (PPI) or H2receptor-antagonists (H2RA), or prokinetic agents.
OBJECTIVE: A decision tree analytic model for comparing economic and clinical outcomes of GERD treatment strategies using continuous or intermittent therapy with PPI, H2RA, or prokinetic agents was developed.
METHODS: Two decision tree models were constructed. One compared four continuous drug therapies; the other compared four intermittent drug treatments. Base values for heal rates and relapse frequencies were determied by analysis of published clinical data. Costs were drug, physician visit, endoscopy, and surgery costs. Clinical outcomes (percent of patients asymptomatic) and economic outcomes (direct costs) were determined at 12 months.
RESULTS: The four continuous treatment strategies resulted in 99–100% asymptomatic patients at 1 year whereas the four intermittent strategies resulted in 76–80% asymptomatic patients at 1 year. At 1 year, the costs per asymptomatic patient, for continuous treatment strategies, were $1069, $1083, $1164, and $1193 for omeprazole 20 mg daily initially followed by omeprazole 10 mg, omeprazole 20 mg, or ranitidine 300 mg daily, or ranitidine 300 mg daily continously, respectively, and for intermittent strategy, were $1299, $1304, $1353, and $1455 for omeprazole 20 mg, cisapride 40 mg daily followed by omeprazole for failures, ranitidine 300 mg daily followed by omeprzole for failures, and ranitidine 300 mg daily followed by ranitidine 600 mg daily. Sensitivity analyses showed omeprazole cost and healing rate to have the greatest impact on the cost of treatment.
CONCLUSIONS: These GERD decision tree analytic models are useful tools for comparing economic and clinical outcomes of drug treatment strategies over a wide range of costs and clinical efficacies.  相似文献   
998.
999.
合成了20个O,O’-二烷基-O-”-(取代苯乙睛肟)磷酸酯、硫代磷酸酯,并分别与杀螺剂氯硝柳胺组成复方,进行室内杀螺试验,初步结果表明,化合物V4、7、12、18有明显杀螺增效作用,其中V12可使氯硝柳胺的杀螺效果提高3.8l倍。同时发现化合物V2、10、13单独使用时,也有良好的杀螺作用。  相似文献   
1000.
Although coronary angiography has been the gold standard for assessing coronary artery stenoses, it yields information primarily about the anatomical severity of coronary artery disease, which frequently does not correlate with its physiological severity. Coronary interventions (PTCA, atherectomy, laser, etc.) are performed primarily to improve coronary flow physiology. Coronary flow physiology may be a more important end point than angiography following coronary interventions that were performed to normalize coronary flow physiology. In addition, the physiological significance of angiographically intermediate stenoses should he assessed before proceeding with catheter-based revascularization. Currently, the Doppler guidewire is available for routine clinical assessment of coronary flow physiology in the Cardiac Catheterization Lab. Several Doppler measurements have been used to assess the physiological effect of a stenosis, including the diastolic-systolic velocity ratio, proximal-distal velocity ratio, coronary flow reserve, continuity equation, and the hyperemic diastolic pressure-flow relationship. The Doppler derived coronary flow reserve correlates highly with stress nuclear perfusion images. These Doppler measurements have been made following PTCA, directional atherectomy, rotational atherectomy, and excimer laser. Following coronary interventions, adverse clinical events may be predicted if there is impaired flow physiology or cyclic flow variations. Many of the Doppler measurements used for assessing the lesion severity remain abnormal following successful coronary interventions for reasons unrelated to the lesion. Conversely, normalization of coronary physiology does not guarantee an adequate anatomical result. Further clinical trials will provide a more complete definition of the exact role for coronary flow velocity assessment following coronary interventions. (J Interven Cardiol 1996;9:163–173)  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号